Výsledky vyhledávání

Akademický článek

miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

Autor: Vu TT; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia., Stölzel F; Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, TU Dresden, Dresden, Germany., Wang KW; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia., Röllig C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, TU Dresden, Dresden, Germany., Tursky ML; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia.; St Vincent's Clinical School, Faculty of Medicine UNSW Sydney, Sydney, NSW, Australia., Molloy TJ; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia. t.molloy@amr.org.au.; St Vincent's Clinical School, Faculty of Medicine UNSW Sydney, Sydney, NSW, Australia. t.molloy@amr.org.au., Ma DD; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia. d.ma@amr.org.au.; St Vincent's Clinical School, Faculty of Medicine UNSW Sydney, Sydney, NSW, Australia. d.ma@amr.org.au.

Publikováno v: Leukemia [Leukemia] 2021 Jul; Vol. 35 (7), pp. 1933-1948. Date of Electronic Publication: 2020 Dec 01.

Zobrazit plný text záznamu

Akademický článek

Direct Comparison of Four Hematopoietic Differentiation Methods from Human Induced Pluripotent Stem Cells.

Autor: Tursky ML; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia., Loi TH; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia., Artuz CM; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia., Alateeq S; Stem Cell Engineering Group, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia., Wolvetang EJ; Stem Cell Engineering Group, Australian Institute for Bioengineering and Nanotechnology, Brisbane, QLD 4072, Australia., Tao H; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia., Ma DD; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia. Electronic address: d.ma@amr.org.au., Molloy TJ; Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Hematology and BM Transplant, St Vincent's Hospital, Level 8, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia. Electronic address: t.molloy@amr.org.au.

Publikováno v: Stem cell reports [Stem Cell Reports] 2020 Sep 08; Vol. 15 (3), pp. 735-748. Date of Electronic Publication: 2020 Aug 06.

Zobrazit plný text záznamu

Akademický článek

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Autor: Brockwell NK; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia.; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; 3Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, Melbourne, Australia., Rautela J; 4The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC Australia.; 5Department of Medical Biology, University of Melbourne, Melbourne, VIC Australia., Owen KL; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia.; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; 3Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, Melbourne, Australia., Gearing LJ; 6Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC Australia.; 7Department of Molecular and Translational Science, Monash University, Clayton, VIC Australia., Deb S; Anatpath, Gardenvale, VIC Australia., Harvey K; Cancer Research Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Sydney, NSW Australia., Spurling A; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia.; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; 3Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, Melbourne, Australia., Zanker D; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia.; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; 3Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, Melbourne, Australia., Chan CL; Cancer Research Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Sydney, NSW Australia., Cumming HE; 6Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC Australia.; 7Department of Molecular and Translational Science, Monash University, Clayton, VIC Australia., Deng N; Cancer Research Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Sydney, NSW Australia., Zakhour JM; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia., Duivenvoorden HM; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia., Robinson T; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia., Harris M; 10Monash Health, Clayton, VIC Australia., White M; 10Monash Health, Clayton, VIC Australia., Fox J; 10Monash Health, Clayton, VIC Australia.; 11Monash Health School of Clinical Sciences, Monash University, Clayton, VIC Australia., Ooi C; 10Monash Health, Clayton, VIC Australia., Kumar B; 10Monash Health, Clayton, VIC Australia., Thomson J; Penninsula Health, Frankston, VIC Australia., Potasz N; Penninsula Health, Frankston, VIC Australia., Swarbrick A; Cancer Research Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Sydney, NSW Australia., Hertzog PJ; 6Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC Australia.; 7Department of Molecular and Translational Science, Monash University, Clayton, VIC Australia., Molloy TJ; 13St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW Australia.; 14St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW Australia., Toole SO; Cancer Research Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Sydney, NSW Australia.; 15Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW Australia.; 16Sydney Medical School, University of Sydney, Sydney, NSW Australia.; Australian Clinical Labs, Bella Vista, NSW Australia., Ganju V; 6Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC Australia.; 7Department of Molecular and Translational Science, Monash University, Clayton, VIC Australia.; 10Monash Health, Clayton, VIC Australia., Parker BS; 1Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC Australia.; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; 3Cancer Immunology and Therapeutics Programs, Peter MacCallum Cancer Centre, Melbourne, Australia.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2019 Aug 29; Vol. 3, pp. 21. Date of Electronic Publication: 2019 Aug 29 (Print Publication: 2019).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání